Cognition Therapeutics secures 20-year US patent for Alzheimer’s and dementia drug

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Cognition Therapeutics announced on 16 June 2026 that the United States Patent and Trademark Office has issued a Notice of Allowance for patent application 19/563,468 covering a polymorphic crystalline form of Zervimesine (CT1812), the company’s lead drug candidate.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE